59 results
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
and efficacy to the satisfaction of applicable regulatory authorities.
Preliminary, initial, or interim results from clinical trials that Tenet … may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
Before obtaining marketing approval from
8-K
EX-99.5
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments
8-K
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
and the remaining 25% of such RSUs vesting on June 27, 2025. The remaining 100,375 RSUs will vest subject to the satisfaction of performance conditions
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect
8-K
EX-99.6
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
-Based RSUs”). The remaining 401,500 RSUs are expected to vest subject to the satisfaction of performance conditions, including the achievement
8-K
4326pyi
26 Jun 24
Submission of Matters to a Vote of Security Holders
4:23pm
DEFA14A
eb4 tcb0oq4b
14 Jun 24
Additional proxy soliciting materials
5:02pm
DEFA14A
w70s91zt
12 Jun 24
Additional proxy soliciting materials
4:42pm
8-K
EX-10.1
jjnren5ketpgj1b7yuwk
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
8-K
5qb0ysh 00gbhw
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
rut6tx5
4 Jun 24
Proxy related to merger
8:00am
PREM14A
qk84z qwwcuey
17 May 24
Preliminary proxy related to merger
4:36pm
10-K/A
wyc88slhd mbc0f
29 Apr 24
Annual report (amended)
4:02pm
DEFA14A
4e1 sn6zt2qd
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
i3zfi1pi26fpuj
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
zc7 txstreb0jmo6l
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
fv3kxcb zlhezvco
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.1
55w4x0f2crbjl
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.4
tmi 2j94cdhf2
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am